Trial Profile
A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2021
Price :
$35
*
At a glance
- Drugs Selatogrel (Primary)
- Indications Coronary artery disease
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 03 Sep 2019 Results published in the Idorsia Pharmaceuticals Media Release.
- 03 Sep 2019 According to an Idorsia Pharmaceuticals Media release, the positive results from this study were presented at the European Society of Cardiology 2019 Congress(ESC 2019).
- 18 Dec 2018 According to an Idorsia media release, the compny will present data from this study at upcoming scientific congress and published in scientific literature.